Related Experiment Videos

Pharmacogenetics of aromatase inhibitors

Kristen D Hadfield1, William G Newman

  • 1Genetic Medicine, Manchester Academic Health Sciences Centre (MAHSC), University of Manchester & Central Manchester University Hospitals NHS Foundation Trust, M13 9WL, UK.

Pharmacogenomics
|April 21, 2012
PubMed

Insights

Genetic variants in aromatase (CYP19A1) and TCL1A influence the effectiveness and side effects of endocrine therapies. Identifying these biomarkers is crucial for optimizing breast cancer treatment.

Area of Science:

  • Endocrinology
  • Pharmacogenomics
  • Oncology

Background:

  • Aromatase inhibitors (AIs) are key endocrine drugs for postmenopausal breast cancer.
  • Research is exploring genetic variants in AI metabolism, particularly CYP19A1 (aromatase), for treatment response.
  • Conflicting results suggest CYP19A1 variants may impact AI efficacy and toxicity.

Purpose of the Study:

  • To investigate the role of genetic variants in AI response and side effects.
  • To identify predictive biomarkers for AI treatment in breast cancer.

Main Methods:

  • Candidate gene approaches assessing CYP19A1 variants.
  • Genome-wide association study identifying a TCL1A variant associated with side effects.

Main Results:

  • CYP19A1 variants show potential but conflicting associations with AI efficacy and toxicity.
  • A specific TCL1A variant is linked to an increased risk of musculoskeletal side effects from AIs.

Conclusions:

  • Genetic variations, including in CYP19A1 and TCL1A, may influence AI treatment outcomes.
  • Predictive biomarkers are essential for personalized endocrine therapy in breast cancer management.

Related Concept Videos

Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...